Selective β1-blockers are commonly given with higher priority than non-selective beta-blockers since several side effects (e.g. bronchospasm) [15] have been ascribed to the blockade of β2-AR and β1-blockers have been proven effective to treat heart failure in large clinical trials [16]. Here, ADRB2 is linked to heart failure.